SCHEMBL1124023

SCHEMBL1124023

O=Cc1ccc(-c2ncccn2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.52
KDM4E B2RXH2 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
LMNA P02545 1/20 0.52
CLK4 Q9HAZ1 1/20 0.47
ADRB2 P07550 1/20 0.47
CYP2A6 P11509 3/20 0.44
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ALDH5A1 P51649 1/20 0.41
ABAT P80404 1/20 0.41
DRD1 P21728 2/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
DRD5 P21918 1/20 0.41
DRD3 P35462 1/20 0.41
MAPT P10636 1/20 0.39
BRD4 O60885 1/20 0.39
KCNJ1 P48048 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20138438 0.87 ALDH1A1 (0.43) ALDH1A1KDM4ESMN1; SMN2LMNACLK4
SCHEMBL11823541 0.80 ALDH1A1 (0.41) ALDH1A1KDM4ESMN1; SMN2LMNACYP2A6
SCHEMBL6685962 0.80 CLK4 (0.64) ALDH1A1KDM4ESMN1; SMN2LMNACLK4
SCHEMBL5799192 0.79 ALDH1A1 (0.52) ALDH1A1KDM4ESMN1; SMN2LMNACLK4
SCHEMBL5799195 0.79 ALDH1A1 (0.52) ALDH1A1KDM4ESMN1; SMN2LMNACLK4
SCHEMBL23637787 0.78 ALDH1A1 (0.46) ALDH1A1KDM4ESMN1; SMN2CYP2A6HSD17B10
SCHEMBL6870760 0.77 CLK4 (0.47) ALDH1A1KDM4ESMN1; SMN2CLK4ADRB2
SCHEMBL16625771 0.77 CLK4 (0.61) ALDH1A1KDM4ESMN1; SMN2LMNACLK4
SCHEMBL1030215 0.77 HSD17B10 (0.52) ALDH1A1KDM4ESMN1; SMN2CYP2A6HSD17B10
SCHEMBL7780699 0.77 ALDH5A1 (0.52) ALDH1A1KDM4ESMN1; SMN2LMNACYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114761452-A Method for preparing hollow covalent organic framework material 浙江大学 2022-07-15 CN claimed
CN-113845646-A Dual-functionalized conjugated microporous polymer based on pyrimidine and cyano, and preparation method and application thereof 浙江时间新材料有限公司 2021-12-28 CN claimed
CN-112898544-A Difunctional conjugated microporous polymer containing pyrimidine ring and cyano and preparation method thereof 台州学院 2021-06-04 CN claimed
CN-112574395-A Conjugated microporous polymer based on 2,4, 6-tri (4-formylphenyl) pyrimidine and preparation method thereof 台州学院 2021-03-30 CN claimed
CN-111848891-A Covalent organic polymer based on 2,4, 6-tri (4-formylphenyl) pyrimidine and preparation method thereof 台州学院 2020-10-30 CN claimed
US-20260078105-A1 Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors ORSOBIO INC (US) 2026-03-19 US disclosed
US-11857550-B2 Benzathine analogs University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2024-01-02 US disclosed
WO-2023065714-A1 PYRIMIDINE- AND CYANO GROUP-BASED BIFUNCTIONAL CONJUGATED MICROPOROUS POLYMER, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 浙江时间新材料有限公司 2023-04-27 WO disclosed
US-11459321-B2 Broad spectrum antiviral compositions and methods EVRYS BIO, LLC (US) 2022-10-04 US disclosed
CN-114761452-A Method for preparing hollow covalent organic framework material 浙江大学 2022-07-15 CN disclosed
CN-113845646-A Dual-functionalized conjugated microporous polymer based on pyrimidine and cyano, and preparation method and application thereof 浙江时间新材料有限公司 2021-12-28 CN disclosed
US-20210315895-A1 BENZATHINE ANALOGS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-10-14 US disclosed
US-6288120-B1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC. 2001-09-11 US disclosed
WO-2001016131-A2 FIVE MEMBERED-RING COMPOUNDS AND UTILIZATION THEREOF IN LIQUID CRYSTAL MIXTURES CLARIANT INTERNATIONAL LTD (CH) 2001-03-08 WO disclosed
EP-1021410-A1 PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS PFIZER INC. (US) 2000-07-26 EP disclosed
EP-1000619-A2 Method for treating glaucoma Pfizer Products Inc. (US) 2000-05-17 EP disclosed
EP-0946501-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1999-10-06 EP disclosed
WO-1999019300-A1 PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS PFIZER INC. (US) 1999-04-22 WO disclosed
WO-1998028264-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1998-07-02 WO disclosed
US-3966801-A ANTIINFLAMMATORY AGENTS WILLIAM H. RORER, INC. (US) 1976-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078105-A1 Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors CPT1B, CBR1, MUSK ALDH1A1 290/4885KDM4E 3207/4885SMN1; SMN2 281/4885
US-11459321-B2 Broad spectrum antiviral compositions and methods IRF3, MAVS, ZC3HAV1 ALDH1A1 2639/4885KDM4E 2307/4885SMN1; SMN2 259/4885
US-11857550-B2 Benzathine analogs HDAC10, CFTR, HBB ALDH1A1 2621/4885KDM4E 1728/4885SMN1; SMN2 3018/4885
US-20210315895-A1 BENZATHINE ANALOGS HDAC10, CFTR, HBB ALDH1A1 2621/4885KDM4E 1728/4885SMN1; SMN2 3018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.